A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

We determined the ability of the multidrug resistance (MDR) reversal agent cyclosporin-A to increase anthracycline drug accumulation in colorectal tumour cells in vitro, using the technique of on-line flow cytometry. Data of four previously untreated patients showed that cyclosporin-A can increase i...

Descripción completa

Detalles Bibliográficos
Autores principales: Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M. E., Planting, A. S., Seynaeve, C., Stoter, G., Nooter, K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977533/
https://www.ncbi.nlm.nih.gov/pubmed/1892765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977533/
https://www.ncbi.nlm.nih.gov/pubmed/1892765

Ejemplares similares